Teachers Advisors LLC increased its holdings in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 20.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,336,728 shares of the medical equipment provider’s stock after buying an additional 229,201 shares during the period. Teachers Advisors LLC’s holdings in Zimmer Biomet were worth $175,740,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in ZBH. JPMorgan Chase & Co. raised its position in shares of Zimmer Biomet by 9.8% in the third quarter. JPMorgan Chase & Co. now owns 11,595,444 shares of the medical equipment provider’s stock valued at $1,524,453,000 after buying an additional 1,033,717 shares in the last quarter. OppenheimerFunds Inc. increased its stake in Zimmer Biomet by 26.9% in the third quarter. OppenheimerFunds Inc. now owns 2,477,866 shares of the medical equipment provider’s stock valued at $325,765,000 after acquiring an additional 524,904 shares during the last quarter. BlackRock Inc. increased its stake in Zimmer Biomet by 3.2% in the third quarter. BlackRock Inc. now owns 15,812,529 shares of the medical equipment provider’s stock valued at $2,078,872,000 after acquiring an additional 485,479 shares during the last quarter. Primecap Management Co. CA increased its stake in Zimmer Biomet by 33.3% in the third quarter. Primecap Management Co. CA now owns 1,713,930 shares of the medical equipment provider’s stock valued at $225,330,000 after acquiring an additional 428,311 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its stake in Zimmer Biomet by 202.9% in the third quarter. Point72 Asset Management L.P. now owns 605,831 shares of the medical equipment provider’s stock valued at $79,649,000 after acquiring an additional 405,831 shares during the last quarter. Institutional investors own 87.86% of the company’s stock.
ZBH has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of Zimmer Biomet from a “hold” rating to a “sell” rating in a research note on Wednesday, October 17th. Morgan Stanley lifted their price objective on shares of Zimmer Biomet from $140.00 to $149.00 and gave the company an “overweight” rating in a research note on Thursday, October 11th. UBS Group initiated coverage on shares of Zimmer Biomet in a research note on Tuesday, November 27th. They issued a “buy” rating and a $140.00 price objective on the stock. Oppenheimer reissued a “buy” rating on shares of Zimmer Biomet in a research note on Monday, August 27th. Finally, Jefferies Financial Group decreased their price objective on shares of Zimmer Biomet from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Monday, October 29th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. Zimmer Biomet presently has an average rating of “Hold” and an average target price of $133.33.
NYSE ZBH opened at $105.62 on Wednesday. The firm has a market cap of $21.88 billion, a price-to-earnings ratio of 13.15, a P/E/G ratio of 2.17 and a beta of 1.16. Zimmer Biomet Holdings Inc has a fifty-two week low of $104.28 and a fifty-two week high of $134.55. The company has a current ratio of 1.89, a quick ratio of 0.96 and a debt-to-equity ratio of 0.70.
Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Friday, October 26th. The medical equipment provider reported $1.63 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.03. The firm had revenue of $1.84 billion for the quarter, compared to analysts’ expectations of $1.84 billion. Zimmer Biomet had a net margin of 22.42% and a return on equity of 12.88%. The company’s revenue was up 1.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.72 earnings per share. As a group, sell-side analysts predict that Zimmer Biomet Holdings Inc will post 7.64 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, January 31st. Shareholders of record on Friday, December 28th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, December 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.91%. Zimmer Biomet’s payout ratio is presently 11.96%.
COPYRIGHT VIOLATION WARNING: “Teachers Advisors LLC Has $175.74 Million Stake in Zimmer Biomet Holdings Inc (ZBH)” was published by Week Herald and is the property of of Week Herald. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://weekherald.com/2018/12/19/teachers-advisors-llc-has-175-74-million-stake-in-zimmer-biomet-holdings-inc-zbh.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Featured Story: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.